Vaxart GAAP EPS of $0.07 beats by $0.28, revenue of $237.2M beats by $34.5M
Source: SeekingAlpha
2026-03-12 16:11:08 ET
More on Vaxart
- Vaxart, Inc. (VXRT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Slideshow
- Quant snapshot: Avino Silver & Gold, Harmony Gold lead strong buys as Angel Studios, Exagen lag
- Seeking Alpha’s Quant Rating on Vaxart
- Historical earnings data for Vaxart
- Financial information for Vaxart
Read the full article on Seeking Alpha
For further details see:
Vaxart GAAP EPS of $0.07 beats by $0.28, revenue of $237.2M beats by $34.5M
Vaxart Inc.
NASDAQ: VXRT
VXRT Trading
-28.75% G/L:
$0.32 Last:
24,017,526 Volume:
$0.412 Open:
VXRT Latest News
March 12, 2026 04:05:00 pm
Vaxart Provides Business Update and Reports Full Year 2025 Financial Results
February 18, 2026 08:00:00 am
Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
January 15, 2026 08:00:00 am
Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants
January 08, 2026 04:01:00 pm
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
VXRT Stock Data
$141,641,208
233,347,888
0.84%
5
16957900%
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
